Vascular Endothelial Growth Factor Overexpression
8
1
1
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
1 terminated out of 8 trials
85.7%
-0.8% vs benchmark
25%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy
Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
Effect of Plasma Rich in Growth Factors on Semen Quality
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence
Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels